Abstract 2154P
Background
The role of lipid levels in the development and outcomes of cancer patients remains unclear in the literature. In this study, we aimed to analyze whether there is a relationship between total cholesterol levels and the survival of hospitalized cancer patients.
Methods
This retrospective observational study included patients admitted to the Medical Oncology Hospitalization Unit at La Paz University Hospital between September 2018 and January 2020. Total cholesterol levels, tumor type, treatment received, and mortality were analyzed.
Results
A total of 839 patients were included, with no differences in gender distribution. The most frequent tumor was lung (20.7%), followed by digestive tumors, including colorectal, esophagogastric, pancreatobiliary, or hepatic (33.4%), and breast (11.4%). The majority of patients were receiving active cancer-specific treatment, with chemotherapy (51.5%) or targeted treatments (18.6%) at the time of admission. At the end of the median follow-up period (31,8 months), 615 deaths had occurred (78.9%). The median overall survival (OS), regardless of tumor type, was 199 days. Having low total cholesterol values (less than 150 mg/dL) increased the risk of mortality by 25.9% compared to having physiological levels (150-200 mg/dL) (p=0.016, CI95% 1.045, 1.518)) with a Hazard Ratio of 1.259. Having high total cholesterol values (above 200 mg/dL) increased the risk of mortality by 30.6% compared to having physiological levels (p=0.036, CI95%(1.017, 1.677)) with an HR of 1.306.
Conclusions
To date, the majority of studies indicate that elevated cholesterol levels in patients with advanced cancer are associated with a higher risk of mortality, both due to a higher burden of comorbidity and the potential effects of cholesterol on oncogenic pathways. On the other hand, low cholesterol levels, possibly reflecting a significant metabolic dysregulation during cachexia, seem to be linked to a worse prognosis as well. Although the mechanisms by which high or low cholesterol levels increase the risk of mortality may differ, their incorporation into prognostic scores can contribute to a more accurate estimation of prognosis in advanced patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2204P - Clinical predictors and inflammatory markers for malignant pleural mesothelioma prognosis: A retrospective study in a Spanish Medical Oncology Unit
Presenter: Mora Guardamagna
Session: Poster session 07
2205P - Tumor-infiltrating lymphocytes score possesses a relation with adjuvant chemo-immunotherapy benefit and cellular morphology in large-cell neuroendocrine carcinoma
Presenter: Zhiwen Luo
Session: Poster session 07
2207P - Mainstream germline genetic testing in routine oncological care of EGFR mutant non-small cell lung cancer in the United Kingdom
Presenter: Hazel O'Sullivan
Session: Poster session 07
2208P - The single-cell proteomic landscape of pulmonary lymphoepithelioma-like carcinoma
Presenter: Chi Cho
Session: Poster session 07
2209P - Mutational status of non-small cell lung cancer in Portugal: A multicentric study
Presenter: Joana Duarte
Session: Poster session 07
2210P - Reprogramming of pyrimidine metabolism drives tumorigenesis in NF2-deficient malignant pleural mesothelioma
Presenter: Duo Xu
Session: Poster session 07
2234P - Local immune-related adverse events (irAEs) are more common in tumor-bearing organs
Presenter: Steve Blum
Session: Poster session 07
2235P - Chemotherapy priming leads to hypermutability and immune surveillance in colorectal cancer
Presenter: Pietro Paolo Vitiello
Session: Poster session 07
2236P - MHC-II neoantigens and copy number alterations (CNA) drive immune checkpoint inhibitor (ICI) response in metastatic melanoma (MM)
Presenter: Benjamin Shum
Session: Poster session 07